

0930-0404 Substance Abuse and Mental Health Services Administration
SAMHSA's Unified Performance Reporting Tool Performance Indicators (SUPRT-P)

1. Summary

SAMHSA requests approval for a non-substantive change to the approved SAMHSA's Unified Performance Reporting Tool (SUPRT) Performance Indicators information collection. The proposed revisions are necessary to align the collection with the policy established by the applicable Executive Order and SAMHSA's "[Dear Colleague Letter](#)" dated April 24, 2026. Specifically, the Dear Colleague Letter identifies fentanyl test strips and xylazine test strips as restricted purchases under SAMHSA grant funding. Accordingly, SAMHSA proposes removing the associated performance indicators from the approved collection to ensure consistency with current program policy and reporting requirements.

Consistent with this guidance, SAMHSA proposes removing the performance indicator questions related to the number of fentanyl test strips distributed and the number of xylazine test strips distributed. These revisions ensure that the approved data collection is consistent with current program policy and reporting expectations. Additionally, a section that was included in the tool to bridge the transition from the legacy programmatic tool to this one titled "IPP" was removed as programs are no longer planning to utilize these indicators.

These changes are administrative in nature and do not alter the overall purpose, methodology associated with the approved information collection. Consistent with guidance received from the OMB Desk Officer, the removal of questions from an approved collection is being submitted as a non-substantive change with documentation identifying the questions removed and the rationale for their removal.

Given the time-sensitive nature of this policy implementation and the need to ensure consistency between the approved instrument and current SAMHSA guidance, SAMHSA respectfully requests expedited review of this non-substantive change.

2. Proposed Changes to the SUPRT-P Performance Tool

This submission proposes the following revisions to the approved SUPRT-P Performance Indicators instrument (see tracked and clean versions):

- **PA 13:** Removed the indicator collecting the number of fentanyl test strips distributed.
- **PA 14:** Removed the indicator collecting the number of xylazine test strips distributed.
- **PA15:** Removed the indicator collecting the number of other drug checking technologies directed by SAMHSA (please specify under comment section) distributed.
- **IO6:** Small typo was corrected changing "late" to "later" - Number of new individuals who achieved a hepatitis C (HCV) cure (SVR4 or later).
- **IPP1-9:** Removed the 9 indicators from the legacy IPP tool so as to not confuse grantees that are transitioning from this tool to SUPRT-P since these items were not assigned to any programs.

No additional revisions are proposed. These changes do not affect the collection's objectives,

respondent population, data collection procedures, or approved burden estimates.

3. List of Attachments

Attachment A. SUPRT-P Performance Indicators – Tracked Changes Version

Attachment B. SUPRT-P Performance Indicators – Clean Version